1. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L, Cao ZW, Wu XL, et al.
    Cancer Research 2006 Dec; 66 (23): 11279-11286.
    | Pubmed
  2. Resources for integrative systems biology: from data through databases to networks and dynamic system models.
    Ng A, Bursteinas B, Gao QO, et al.
    Briefings in Bioinformatics 2006 Dec; 7 (4): 318-330. | Pubmed
  3. Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma.
    Chan KYY, Lai PBS, Squire JA, et al.
    Modern Pathology 2006 Dec.; 19 (12): 1546-1554. | Pubmed
  4. Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2 ‘,5 ‘-oligoadenylate synthetase from prostate cancer cells.
    Molinaro, RJ; Jha, BK; Malathi, K; Varambally, S; Chinnaiyan, AM; Silverman, RH
    Nucleic Acids Res. 2006;34(22):6684-95. Epub 2006 Dec 1. | Pubmed
  5. The HBP1 transcriptional repressor participates in RAS-induced premature senescence.
    Zhang XW, Kim J, Ruthazer R, et al.
    Molecular an Cellular Biology 2006 Nov.; 26 (22): 8252-8266. | Pubmed
  6. A Novel Role of Myosin VI in Human Prostate Cancer.
    Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J
    American J Pathology. 2006 Nov; 169(5):1843-54. | Pubmed
  7. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.
    Rubin MA, Chinnaiyan AM.
    Laboratory Inestigation 2006 Nov; 86 (11): 1099-1102. | Pubmed
  8. Evidence of recurrent gene fusions in common epithelial tumors.
    Kumar-Sinha C, Tomlins SA, Chinnaiyan AM
    Trends in Molecular Medicine 2006 Nov.; 12 (11): 529-536. | Pubmed
  9. Strategies for plasma proteomic profiling of cancers.
    Omenn, GS
    Proteomics. 2006 Oct;6(20):5662-73. | Pubmed
  10. Comparative microarray analysis.
    Larsson O, Wennmalm K, Sandberg R
    Omics-A Journal of Integrative Biology 2006 Sep; 10 (3): 381-397. | Pubmed
  11. Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis.
    Zhao WM, Seki A, Fang GW.
    Molecular Biology of the Cell 2006 Sep; 17 (9): 3881-3896. | Pubmed
  12. Differential proteomic alterations between localised and metastatic prostate cancer.
    Taylor BS, Varambally S, Chinnaiyan AM.
    British Journal of Cancer 2006 Aug; 95 (4): 425-430. | Pubmed
  13. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
    Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K.
    Nature. 2006 Jul 20;442(7100):307-11. | Pubmed
  14. Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue.
    Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G, Rubin MA.
    Arch Pathol Lab Med. 2006 Jul;130(7):989-96. | Pubmed
  15. CCL2 is a potent regulator of prostate cancer cell migration and proliferation.
    Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ.
    Neoplasia. 2006 Jul; 8(7):578-86. | Pubmed
  16. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma.
    Guo L, Ma Y, Ward R, Castranova V, Shi X, Qian Y.
    Clinical Cancer Res. 2006 Jun 1;12(11 Pt 1):3344-54. | Pubmed
  17. Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism.
    Kim SW, Mangold U, Waghorne C, Mobascher A, Shantz L, Banyard J, Zetter BR.
    J Cell Science. 2006 Jun 15;119(Pt 12):2583-91. | Pubmed
  18. Identical probes on different high-density oligonucleotide microarrays can produce different measurements of gene expression.
    Zhang L, Yoder SJ, Enkemann SA.
    BMC Genomics 2006 Jun; 7: Art. No. 153. | Pubmed
  19. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
    Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, Squire JA.
    Neoplasia. 2006 Jun;8(6):465-9. | Pubmed
  20. Identification of genes expressed differentially in an in vitro human lung carcinogenesis model.
    Lacroix L, Feng G, Lotan R.
    Cancer Biology & Therapy 2006 Jun; 5 (6): 665-673. | Pubmed
  21. Cross-platform classification in microarray-based leukemia diagnostics.
    Nilsson, B; Andersson, A; Johansson, M; Fioretos, T
    Haematologica. 2006 Jun;91(6):821-4. | Pubmed
  22. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.
    Kaposi-Novak, P; Lee, JS; Gomez-Quiroz, L; Coulouarn, C; Factor, VM; Thorgeirsson, SS
    J Clin Invest. 2006 Jun;116(6):1582-95. Epub 2006 May 18. | Pubmed
  23. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
    Collard RL, Harya NS, Monzon FA, Maier CE, O’Keefe DS.
    Prostate. 2006 May 15;66(7):687-95 | Pubmed
  24. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.
    Zhang L, Huang J, Yang N, Liang S, Barchetti A, Giannakakis A, Cadungog MG, O’Brien-Jenkins A, Massobrio M, Roby KF, Katsaros D, Gimotty P, Butzow R, Weber BL, Coukos G.
    Cancer Res. 2006 May 1;66(9):4627-35 | Pubmed
  25. Functional screening for proapoptotic genes by reverse transfection cell array technology.
    Mannherz O, Mertens D, Hahn M, Lichter P.
    Genomics. 2006 May;87(5):665-72. | Pubmed
  26. Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene.
    Li, Z; Szabolcs, M; Terwilliger, JD; Efstratiadis, A
    Carcinogenesis. 2006 May;27(5):1054-67. Epub 2006 Jan 9. | Pubmed
  27. Prostate-specific antigen, high-molecular-weight cytokeratin (Clone 34 beta E12), and/or p63 - An optimal lmmunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
    Kunju, LP; Mehra, R; Snyder, M; Shah, RB
    Am J Clin Pathol. 2006 May;125(5):675-81. | Pubmed
  28. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.
    Kuefer, R; Day, KC; Kleer, CG; Sabel, MS; Hofer, MD; Varambally, S; Zorn, CS; Chinnaiyan, AM; Rubin, MA; Day, ML
    Neoplasia. 2006 Apr;8(4):319-29. | Pubmed
  29. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
    Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, Wallace M, Hagen J, Quelle DE, Watson MA, Perry A, Gutmann DH, Ratner N.
    Cancer Res. 66, 2584-2591, Mar 1, 2006. | Pubmed
  30. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.
    O’Donnell, KA; Yu, DN; Zeller, KI; Kim, JW; Racke, F; Thomas-Tikhonenko, A; Dang, CV
    Mol Cell Biol. 2006 Mar;26(6):2373-86. | Pubmed
  31. ETS-TMPRSS2 fusion gene products in prostate cancer.
    Ahlers, CM; Figg, WD
    Cancer Biol Ther. 2006 Mar;5(3):254-5. Epub 2006 Mar 13. | Pubmed
  32. Low pH induces co-ordinate regulation of gene expression in oesophageal cells.
    Duggan SP, Gallagher WM, Fox EJ, Abdel-Latif MM, Reynolds JV, Kelleher D.
    Carcinogenesis. 2006 Feb;27(2):319-27. | Pubmed
  33. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
    Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, Tindall DJ, Young CY.
    Clinical Cancer Res. 2006 Feb . 15;12(4):1128-36. | Pubmed
  34. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
    Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, Oberthuer A, Berthold F, Wei JS, Khan J, Schwab M, Westermann F.
    Clinical Cancer Res. 2006 Jan 1;12(1):131-8. | Pubmed
  35. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.
    Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M.
    Oncogene. 2006 Jan 19;25(3):359-69. | Pubmed
  36. Defining aggressive prostate cancer using a 12-gene model.
    Bismar TA, Demichelis F, Riva A, et al.
    Neoplasia 2006 Jan; 8 (1): 59-68. | Pubmed
  37. Molecular markers for discrimination of benign and malignant follicular thyroid tumors.
    Fryknas M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Hoog A, Larsson C, Grimelius L, Wallin G, Pettersson U, Isaksson A.
    Tumor Biol. 2006;27(4):211-20. | Pubmed
  38. Integrative biology of prostate cancer progression.
    Tomlins SA, Rubin MA, Chinnaiyan AM
    Annual Review of Pathology-Mechanisms of Disease 1 (1): 243-271 2006. | Pubmed
  39. Molecular analysis of minimally invasive follicular carcinomas by gene profiling.
    Lubitz CC, Gallagher LA, Finley DJ, Zhu B, Fahey TJ
    Surgery. 2005 Dec;138(6):1042-8. | Pubmed
  40. A review of the past, present, and future directions of neoplasia.
    Rehemtulla, A., and Ross, B. D.
    Neoplasia 2005 Dec; 7(12), 1039-1046. | Pubmed
  41. The octamer binding transcription factor Oct-1 is a stress sensor.
    Tantin D, Schild-Poulter C, Wang V, Hache RJ, Sharp PA.
    Cancer Res. 2005 Dec 1;65(23):1-8. | Pubmed
  42. Two different global gene expression profiles in cancer cell lines established from etiologically different oral carcinomas.
    Ruutu, M., Johansson, B., Grenman, R., Syrjanen, S.
    Oncol Rep 2005 Dec; 14(6), 1511-1517. | Pubmed
  43. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
    Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG.
    Cancer Res. 2005 Dec 15; 65(24):11259-64. | Pubmed
  44. The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.
    Zeidler, M., Varambally, S., Cao, Q., Chinnaiyan, A. M., Ferguson, D. O., Merajver, S. D., Kleer, C. G.
    Neoplasia 2005 Dec. 7(11), 1011-1019. | Pubmed
  45. Overlapping gene expression in fetal mouse intestine development and human colorectal cancer.
    Hu M, Shivdasani RA.
    Cancer Res. 2005 Oct 1;65(19):8715-22. | Pubmed
  46. Identification of MMP-15 as an anti-apoptotic factor in cancer cells.
    Abraham R, Schafer J, Rothe M, Bange J, Knyazev P, Ullrich A.
    J Biol Chem. 2005 Oct 7;280(40):34123-32. | Pubmed
  47. List of lists-annotated (LOLA): a database for annotation and comparison of published microarray gene lists.
    Cahan, P., Ahmad, A. M., Burke, H., Fu, S., Lai, Y., Florea, L., Dharker, N., Kobrinski, T., Kale, P., and McCaffrey, T. A.
    Gene 2005 Oct; 360, 78-82. | Pubmed
  48. Mechanisms of PECAM-1-mediated cytoprotection and implications for cancer cell survival.
    Bergom C, Gao C, Newman PJ.
    Leuk Lymphoma. 2005 Oct; 46(10):1409-21. | Pubmed
  49. Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data.
    Xu, L., Tan, A. C., Naiman, D. Q., Geman, D., and Winslow, R. L.
    Bioinformatics 2005 Oct; 21, 3905-3911. | Pubmed
  50. Autoantibody signatures in prostate cancer.
    Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM.
    NEJM. 2005 Sep.; (2): 1224-1235. | Pubmed
  51. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
    Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET.
    Cancer Res. 2005 Sep 1;65(17):7554-60. | Pubmed
  52. Functional profiling: from microarrays via cell-based assays to novel tumor relevant modulators of the cell cycle.
    Arlt D, Huber W, Liebel U, Schmidt C, Majety M, Sauermann M, Rosenfelder H, Bechtel S, Mehrle A, Bannasch D, Schupp I, Seiler M, Simpson JC, Hahne F, Moosmayer P, Ruschhaupt M, Guilleaume B, Wellenreuther R, Pepperkok R, Sultmann H, Poustka A, Wiemann S.
    Cancer Res. 2005 Sep; 65(17):7733-42. | Pubmed
  53. Emerging issues of the expression profiling technologies for the study of gynecologic cancer.
    Pappa, K. I., and Anagnou, N. P.
    Am J Obstet Gynecol 2005 Sep.;. 193, 908-918. | Pubmed
  54. TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas.
    Kleivi K, Diep CB, Pandis N, Heim S, Teixeira MR, Lothe RA.
    J Pathol. 2005 Sep ; 207(1):14-9. | Pubmed
  55. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?
    Hashimoto, Y., Skacel, M., and Adams, J. C.
    Int J Biochem Cell Biol 2005 Sep; 37, 1787-1804. | Pubmed
  56. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response.
    Laganiere, J., Deblois, G., Lefebvre, C., Bataille, A. R., Robert, F., and Giguere, V.
    Proc Natl Acad Sci USA 2005 Aug; 102,11651-11656. | Pubmed
  57. GEMS: a system for automated cancer diagnosis and biomarker discovery from microarray gene expression data.
    Statnikov, A., Tsamardinos, I., Dosbayev, Y., and Aliferis, C. F.
    Int J Med Inform 2005 Aug; 74, 491-503. | Pubmed
  58. Storing, linking, and mining microarray databases using SRS.
    Veldhoven, A., de Lange, D., Smid, M., de Jager, V., Kors, J. A., and Jenster, G.
    BMC Bioinformatics 2005 Jul; 6, 192. | Pubmed
  59. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals.
    Alpy, F., and Tomasetto, C.
    J Cell Science 2005 Jul; 118, 2791-2801. | Pubmed
  60. High-resolution genomic profiles of human lung cancer.
    Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA.
    Proc Natl Acad Sci U S A. 2005 Jul; 102(27):9625-30. | Pubmed
  61. Microarray-based classification of diffuse large B-cell lymphoma.
    Poulsen CB, Borup R, Nielsen FC, Borregaard N, Hansen M, Gronbaek K, Moller MB, Ralfkiaer E.
    European J Haematology. 2005 Jun; 74(6):453-65. | Pubmed
  62. A genetic screen for candidate tumor suppressors identifies REST.
    Westbrook, T. F., Martin, E. S., Schlabach, M. R., Leng, Y., Liang, A. C., Feng, B., Zhao, J. J., Roberts, T. M., Mandel, G., Hannon, G. J., et al.
    Cell 2005 Jun; 121, 837-848. | Pubmed
  63. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers.
    Haruki, N., Kawaguchi, K. S., Eichenberger, S., Massion, P. P., Olson, S., Gonzalez, A., Carbone, D. P., and Dang, T. P.
    Cancer Research 2005 May; 65, 3555-3561. | Pubmed
  64. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification.
    Bergmann, S., Royer-Pokora, B., Fietze, E., Jurchott, K., Hildebrandt, B., Trost, D., Leenders, F., Claude, J. C., Theuring, F., Bargou, R., et al.
    Cancer Research 2005 May; 65, 4078-4087. | Pubmed
  65. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.
    Mayeur, G. L., Kung, W. J., Martinez, A., Izumiya, C., Chen, D. J., and Kung, H. J.
    J Biol Chem 2005 Mar; 280, 1-1. | Pubmed
  66. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
    Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R.
    Cancer Research. 2005 Feb 15; 65(4):1479-88. | Pubmed
  67. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
    Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM.
    Oncogene. 2005 Feb 3;24(6):1053-65. | Pubmed
  68. Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty.
    Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA, Creighton CJ, Menon A, Rubin MA, Chinnaiyan AM.
    FASEB J. 2005 Feb;19(2):243-5. | Pubmed
  69. A database for tracking toxicogenomic samples and procedures.
    Bao, W., Schmid, J. E., Goetz, A. K., Ren, H., and Dix, D. J.
    Reproductive Toxicology 2005 Jan.-Feb.; 19, 411-419. | Pubmed
  70. L2L: a simple tool for discovering the hidden significance in microarray expression data.
    Newman, J. C., and Weiner, A. M.
    Genome Biol 2005. 6(9), R81. | Pubmed
  71. Common and contrasting genomic profiles among the major human lung cancer subtypes
    Tonon, G; Brennan, C; Protopopov, A; Maulik, G; Feng, B; Zhang, Y; Khatry, DB; You, MJ; Aguirre, AJ; Martin, ES; Yang, Z; Ji, H; Chin, L; Wong, KK; DePinho, RA
    Cold Spring Harb Symp Quant Biol. 2005;70:11-24. | Pubmed
  72. The tumor protein D52 family: many pieces, many puzzles.
    Boutros, R., Fanayan, S., Shehata, M., and Byrne, J. A.
    Biochem Biophys Res Commun 2004 Dec; 325, 1115-1121. | Pubmed
  73. Splicing factors are differentially expressed in tumors.
    Kirschbaum-Slager N, Lopes GM, Galante PA, Riggins GJ, de Souza SJ.
    Genet Mol Res. 2004 Dec 30;3(4):512-20. | Pubmed
  74. Adrogen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.
    Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ.
    Cancer Res. 2004 Dec; 64(24):9209-16. | Pubmed
  75. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies.
    Shi, L., Tong, W., Goodsaid, F., Frueh, F. W., Fang, H., Han, T., Fuscoe, J., and Casciano, D. A.
    Expert Rev Mol Diagnostics 2004 Nov; 4, 761-777. | Pubmed
  76. Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells.
    Guzey M, Luo J, Getzenberg RH.
    J Cell Biochem. 2004 Oct 1;93(2):271-85. | Pubmed
  77. JAGGED1 expression is associated with prostate cancer metastasis and recurrence.
    Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC.
    Cancer Res. 2004 Oct; 64(19):6854-7. | Pubmed
  78. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin.
    Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux QL, Hampton GM.
    Oncogene 2004 Aug.; 23 (39): 6621-6629. | Pubmed
  79. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.
    Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H.
    Hum Mol Genet. 2004 Jul;13(13):1303-13. | Pubmed
  80. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck.
    Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM.
    Cancer Res. 2004 Jan 1;64(1):55-63. | Pubmed